AstraZeneca Financial Statements From 2010 to 2025

Stocks . UK . 
Stock . AstraZeneca PLC
AZN Stock   11,708  256.00  2.14%   
AstraZeneca PLC financial statements provide useful quarterly and yearly information to potential AstraZeneca PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AstraZeneca PLC financial statements helps investors assess AstraZeneca PLC's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AstraZeneca PLC's valuation are summarized below:
Gross Profit
44.4 B
Profit Margin
0.1301
Exchange Market
LSE - MAIN MARKET
Market Capitalization
185.5 B
Enterprise Value Revenue
4.67
There are over ninety-one available fundamental signals for AstraZeneca PLC, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of AstraZeneca PLC's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

AstraZeneca PLC Total Revenue

56.78 Billion

Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7 B, Interest Expense of 1.8 B or Total Revenue of 56.8 B, as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

AstraZeneca PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets109.2 B104 B69.9 B
Slightly volatile
Short and Long Term Debt Total31.6 B30.1 B18.9 B
Slightly volatile
Total Current Liabilities29.3 B27.9 B18.9 B
Slightly volatile
Total Stockholder Equity42.8 B40.8 B23.7 B
Slightly volatile
Property Plant And Equipment Net7 B11.6 B7.6 B
Slightly volatile
Net Debt25.9 B24.6 B13.1 B
Slightly volatile
Accounts Payable23.6 B22.5 B5.4 B
Slightly volatile
Cash4.7 B5.5 B5.8 B
Very volatile
Non Current Assets Total82.1 B78.2 B50.9 B
Slightly volatile
Cash And Short Term Investments5.8 B5.7 B6.6 B
Pretty Stable
Common Stock Shares Outstanding1.4 B1.6 B1.3 B
Slightly volatile
Short Term Investments157.7 M166 M773.9 M
Slightly volatile
Liabilities And Stockholders Equity109.2 B104 B69.9 B
Slightly volatile
Non Current Liabilities Total37.1 B35.3 B26.8 B
Slightly volatile
Inventory2.8 B5.3 B3.4 B
Slightly volatile
Other Current Assets15.6 B14.9 B5.7 B
Slightly volatile
Total Liabilities66.3 B63.2 B45.7 B
Slightly volatile
Property Plant And Equipment Gross7.3 B11.6 B8.1 B
Slightly volatile
Total Current Assets15.7 B25.8 B18.2 B
Slightly volatile
Short Term Debt1.6 B2.5 B2.4 B
Slightly volatile
Other Assets5 B4.8 B3.3 B
Slightly volatile
Common Stock Total Equity296 M295.2 M314.8 M
Pretty Stable
Common Stock297.7 M349.2 M329.4 M
Slightly volatile
Intangible Assets39 B37.2 B25 B
Slightly volatile
Other Liabilities6.7 B9.8 B8.9 B
Slightly volatile
Long Term Debt27.8 B26.5 B16.1 B
Slightly volatile
Good Will22.1 B21 B13.5 B
Slightly volatile
Property Plant Equipment7.9 B10.9 B7.7 B
Slightly volatile
Deferred Long Term Liabilities3.1 B4.5 B3.2 B
Slightly volatile
Long Term Investments1.1 B1.7 B1.1 B
Slightly volatile
Short and Long Term Debt2.5 B2.2 B2 B
Slightly volatile
Capital Surpluse6.4 B9.2 B5.9 B
Slightly volatile
Net Invested Capital55.1 B69.4 B42.8 B
Slightly volatile
Capital Stock396.5 M446.2 M344.6 M
Slightly volatile

AstraZeneca PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7 B6.7 B3.7 B
Slightly volatile
Interest Expense1.8 B1.7 B1.2 B
Slightly volatile
Total Revenue56.8 B54.1 B31.4 B
Slightly volatile
Gross Profit46.1 B43.9 B24.9 B
Slightly volatile
Other Operating Expenses46.3 B44.1 B26.1 B
Slightly volatile
Operating Income5.2 B10 B5 B
Very volatile
EBIT5.3 B10.4 B5.1 B
Very volatile
Research Development14.3 B13.6 B7.2 B
Slightly volatile
EBITDA18 B17.1 B9.2 B
Slightly volatile
Total Operating Expenses35.6 B33.9 B19.6 B
Slightly volatile
Net Income3.6 B7 B3.5 B
Very volatile
Selling General Administrative11.6 B20 B11.7 B
Slightly volatile
Cost Of Revenue6.7 B10.2 B6.6 B
Slightly volatile
Net Income Applicable To Common Shares3.2 B3 B3.2 B
Slightly volatile
Selling And Marketing Expenses527.2 M555 M9.9 B
Slightly volatile
Net Income From Continuing Ops7.4 B7 B2.8 B
Slightly volatile
Interest Income480.9 M458 M129.5 M
Slightly volatile
Reconciled Depreciation5.1 B6.7 B4 B
Slightly volatile
Extraordinary Items492.8 M554.4 M604.5 M
Slightly volatile

AstraZeneca PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow7.6 B7.3 B3.7 B
Slightly volatile
Begin Period Cash Flow4.5 B5.6 B5.9 B
Pretty Stable
Depreciation7 B6.7 B3.9 B
Slightly volatile
Capital Expenditures4.8 B4.6 B2.6 B
Slightly volatile
Total Cash From Operating Activities12.5 B11.9 B6.4 B
Slightly volatile
End Period Cash Flow4.2 B5.4 B5.6 B
Very volatile
Dividends Paid3.5 B4.6 B3.6 B
Slightly volatile
Stock Based Compensation340.4 M665.9 M312.3 M
Slightly volatile

AstraZeneca Fundamental Market Drivers

Forward Price Earnings16.1551
Cash And Short Term Investments5.7 B

About AstraZeneca PLC Financial Statements

AstraZeneca PLC stakeholders use historical fundamental indicators, such as AstraZeneca PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in AstraZeneca PLC's assets and liabilities are reflected in the revenues and expenses on AstraZeneca PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 B1.3 B
Total Revenue54.1 B56.8 B
Cost Of Revenue10.2 B6.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CSXCSX Corporation
ETONEton Pharmaceuticals
ALLTAllot Communications

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY